Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Blood (2023) 142 (Supplement 1): 3028.

https://doi.org/10.1182/blood-2023-187847

Published: 2023

Journal Articles

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Zoe Begun, Emilie Thompson, Tingting Zhan, Gina Keiffer, Margaret Kasner, Lindsay Wilde

Blood (2023) 142 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2023-184610

Published: 2023

Journal Articles

Retrospective Analysis of the Relationship between Time to Anti-Resorptive Therapy and Incidence of Skeletal Related Events in Patients with Multiple Myeloma

Kelly Hughes, Abdullateef O Abdulkareem, MD MPH, Niketa Raj, Adam Barsouk, Tingting Zhan, PhD, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143340

Published: 2020

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Gina Keiffer, MD, Kelly Hughes, Tingting Zhan, PhD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140055

Published: 2020

Journal Articles

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Jonathan Pan, MD, Sushil Ghimire, MD, Molly Halloran, MD, Alexander Xu, BA, Tingting Zhan, PhD, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143146

Published: 2020

Journal Articles

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Jonathan Pan, MD, Sushil Ghimire, MD, Tingting Zhan, PhD, Onder Alpdogan, MD, Andrew E. Chapman, DO, Matthew Carabasi, MD, Ubaldo Martinez-Outschoorn, MD, Lewis J. Rose, MD, Michael Ramirez, MD, John L Wagner, MD, Barbara Pro, MD, Mark A. Weiss, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD

Blood (2019) 134 (Supplement_1): 5318.

https://doi.org/10.1182/blood-2019-125836

Published: 2019

NARROW

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Retrospective Analysis of the Relationship between Time to Anti-Resorptive Therapy and Incidence of Skeletal Related Events in Patients with Multiple Myeloma

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Retrospective Analysis of the Relationship between Time to Anti-Resorptive Therapy and Incidence of Skeletal Related Events in Patients with Multiple Myeloma

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only